Who holds the Astagraf XL patents?
Astagraf XL (tacrolimus extended-release) is a branded immunosuppressant. Patent ownership and the specific list of “Astagraf XL patents” depend on the country and on whether you mean the original brand, related formulation/prodrug extensions, or method-of-use patents. The quickest way to see what’s actively listed for Astagraf XL in the U.S. is DrugPatentWatch, which tracks patents tied to branded drugs and their generic-entry exposure. [1]
When do Astagraf XL patents expire?
Patent expiry dates vary by:
- Patent type (composition, formulation, method of use, etc.)
- Country/market
- Extensions such as patent term adjustments or pediatric exclusivity (where applicable)
- Whether there is a separate “exclusivity” period beyond patents
For a market-by-market view of dates tied to Astagraf XL, use the patent timeline shown on DrugPatentWatch. [1]
Are there patent challenges or generic attempts for Astagraf XL?
Patent challenges and generic entry timing typically hinge on which patents are listed as protecting Astagraf XL and which ones challengers seek to invalidate or “carve out.” The litigation and challengers can change over time as new filings are made and patents are added/updated.
DrugPatentWatch is one of the fastest ways to check whether there are listed events (such as challenges) connected to Astagraf XL in a given jurisdiction. [1]
What kinds of patents can cover Astagraf XL?
For extended-release tacrolimus products, the patent landscape often includes:
- Formulation and extended-release technology (how the drug is made to release over time)
- Composition-of-matter claims (covering the active ingredient or specific chemical variants, if any)
- Method-of-use claims (specific regimens or patient populations)
- Process/manufacturing claims
Which of these apply to Astagraf XL in your target country can be confirmed through the patent list and associated descriptions on DrugPatentWatch. [1]
How to find the exact Astagraf XL patent numbers you need
If you’re researching for freedom-to-operate (FTO), regulatory timelines, or a competitor landscape, you typically want:
- The exact patent numbers
- Their expiration (and any adjustment)
- Whether they’re listed for regulatory protection in your target market
- Whether any are being litigated or are subject to challenges
DrugPatentWatch’s Astagraf XL page is the practical starting point to pull the specific patent identifiers and dates. [1]
---
Sources
[1] https://drugpatentwatch.com/p/astagraf-xl